Skip to main content
. 2013 Mar 15;207(Suppl 1):S26–S32. doi: 10.1093/infdis/jis764

Figure 1.

Figure 1.

Sustained virologic response at 12 weeks after stopping therapy, based on an analysis of a phase IIa study of telaprevir plus combined pegylated interferon alfa (PegIFN) and ribavirin for the treatment of hepatitis C virus (HCV) infection in human immunodeficiency virus–infected patients